scholarly journals Genomic Landscape and Immunological Profile of Glioblastoma in East Asian Patients

2021 ◽  
Author(s):  
Jean Zhao ◽  
Sheng Zhong ◽  
Bo Wu ◽  
Frank Dubois ◽  
Shanshan Jiang ◽  
...  
Keyword(s):  
East Asian ◽  
Marker Gene ◽  
European Ancestry ◽  
Asian Patients ◽  
Molecular Features ◽  
Immunological Profile ◽  
Genomic Landscape ◽  
Genetic Landscape ◽  
Genetic Features ◽  
East Asian Patients

Abstract While it is well known that Glioblastoma (GBM) shows profound inter- and intra-tumoral heterogeneity, disparities in molecular features across ancestry groups have been largely overlooked. We collected a large cohort of GBM samples from East Asian patients (EAS-GBM) and performed genomic and transcriptomic analyses of these samples (EAS-GBM, n=443). Further characterization and comparative analysis of the EAS-GBM with the predominantly European-ancestry TCGA GBM dataset (EUR-GBM, n=383) revealed differential genomic and genetic landscape and immunological profile of EAS-GBM from EUR-GBM. EAS-GBM showed an enrichment for NF1, H3F3A, TP53 and ATRX mutations compared to EUR-GBM. Transcriptomic clustering revealed distinct EAS-GBM specific subtypes, namely Proliferative (PL), Neuron-Synaptic (NS), Metabolic (MB) and Immunomodulatory (IM). Notably, the classic subtype of EUR-GBMs with EGFR as its main marker gene was absent in EAS-GBMs, Moreover, the IM subgroup in EAS-GBM with an expression profile that has been previously associated with response to immunotherapy in cancers. Together, our comprehensive characterization revealed the unique genomic and genetic features of EAS-GBMs, providing mechanistic rationale in patient stratification for molecular targeted therapy and drug development in the era of personalized medicine.

scholarly journals P70.01 Distribution of CCND1 Mutations in East Asian Patients With Non-Small Cell Lung Cancer

2021 ◽  
Vol 16 (3) ◽  
pp. S562-S563
Author(s):  
H. Feng ◽  
C. Xu ◽  
W. Wang ◽  
D. Wang ◽  
Y. Zhu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
East Asian ◽  
Small Cell ◽  
Small Cell Lung ◽  
Asian Patients ◽  
East Asian Patients

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

2021 ◽  
Author(s):  
Toshio Shimizu ◽  
Yasutoshi Kuboki ◽  
Chia-Chi Lin ◽  
Kan Yonemori ◽  
Tomoko Yanai ◽  
...  
Keyword(s):  
Phase 1 ◽  
East Asian ◽  
Phase 1 Study ◽  
Asian Patients ◽  
East Asian Patients

scholarly journals Phase 1 Study of MLN8237 (Alisertib) in Adult East Asian Patients (PTS) with Advanced Solid Tumors or Lymphomas

2013 ◽  
Vol 24 ◽  
pp. ix48
Author(s):  
W.S. Kim ◽  
K. Venkatakrishnan ◽  
T.M. Kim ◽  
C.-C. Lin ◽  
L.S. Thye ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
East Asian ◽  
Advanced Solid Tumors ◽  
Phase 1 Study ◽  
Asian Patients ◽  
East Asian Patients

P70.09 NOTCH1 Mutations in East Asian Patients With Non-Small-Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S1214
Author(s):  
B. Song ◽  
C. Xu ◽  
W. Wang ◽  
D. Wang ◽  
Y. Zhu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
East Asian ◽  
Small Cell ◽  
Small Cell Lung ◽  
Asian Patients ◽  
Notch1 Mutations ◽  
East Asian Patients

Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20015-e20015
Author(s):  
Kihyun Kim ◽  
Chang Ki Min ◽  
Youngil Koh ◽  
Kenichi Ishizawa ◽  
Sung-Hyun Kim ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Disease Progression ◽  
Residual Disease ◽  
East Asian ◽  
Progression Free Survival ◽  
Complete Response ◽  
Efficacy And Safety ◽  
Asian Patients ◽  
Number Of Patients ◽  
East Asian Patients

e20015 Background: The Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) plus carfilzomib and dexamethasone (Kd) significantly improved progression-free survival (PFS) compared with Kd in patients (pts) with relapsed multiple myeloma (RMM) (hazard ratio [HR] 0.53; 99% confidence interval [CI] 0.32–0.89; P= 0.0007). We evaluated the efficacy and safety of Isa-Kd in the East Asian patients (19 Japanese, 27 Korean). Methods: RMM pts who received 1-3 prior lines of therapy were stratified to receive Isa-Kd or Kd. Isa-Kd arm received Isa (10 mg/kg intravenously) weekly for 4 weeks, then every 2 weeks. Both arms received K (20 mg/m2 days 1-2, 56 mg/m2 thereafter) twice-weekly for 3 of 4 weeks, and d (20 mg) twice-weekly. Treatment continued until disease progression or unacceptable adverse events (AE). The primary endpoint was prolongation of PFS. Key secondary endpoints included; very good partial response or better (≥VGPR), complete response (CR) rate and minimal residual disease negativity (MRD–) rate. Results: East Asian pts (25 Isa-Kd, 21 Kd) were randomized. Pt characteristics were similar in the East Asian subgroup compared with the intent to treat (ITT) population (N = 302). Median age (Isa-Kd 64.0 [range 45–83] years vs Kd 60.0 [range 33–73] years); median prior lines Isa-Kd 2.0 (range 1–3) vs Kd 1.0 (range 1–3); refractory to lenalidomide 16.0% Isa-Kd vs 47.6% Kd; refractory to PI 20.0% Isa-Kd vs 33.3% Kd; high-risk cytogenetics 48.0% Isa-Kd vs 42.9% Kd. After a median follow-up of 20.7 months, the addition of Isa to Kd improved ≥VGPR, CR and MRD– rates (Table). The HR 0.64 (95%CI: 0.231-1.764) for disease progression or death favored Isa-Kd. Grade ≥3 AEs were observed in 79.2% Isa-Kd vs 55.0% Kd pts, serious TEAEs in 45.8% Isa-Kd vs 50.0% Kd; TEAEs leading to treatment discontinuation were lower in the Isa-Kd group (4.2% Isa-Kd vs 10.0% Kd). Overall, 64.0% Isa-Kd vs 42.9% Kd pts were still receiving treatment. Conclusions: Efficacy and safety results of Isa-Kd in East Asian pts are consistent with the results of the overall IKEMA population, in which significantly better efficacy (PFS, CR, ≥VGPR and MRD– rate) was reported in favor of Isa-Kd without an increase in the number of patients with serious TEAEs or discontinuations. Isa-Kd is a potential treatment option for East Asian pts with RMM. Clinical trial information: NCT03275285. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document